Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling

Journal of Clinical Oncology

Volumn 23, Issue 4, 2005, Pages 732-740

  Jansen, Maurice P H M ^a   Foekens, John A ^a   Van Staveren, Iris L ^a   Dirkzwager Kiel, Maaike M ^a   Ritstier, Kirsten ^a   Look, Maxime P ^a   Meijer Van Gelder, Marion E ^a   Sieuwerts, Anieta M ^a   Portengen, Henk ^a   Dorssers, Lambert C J ^a   Klijn, Jan G M ^a   Berns, Els M J J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER SURVIVAL; DISEASE CLASSIFICATION; DISEASE COURSE; DNA MICROARRAY; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR VOLUME; BREAST TUMOR; CLASSIFICATION; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; TAMOXIFEN; TREATMENT FAILURE;

EID: 20044377912     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.145     Document Type: Article

References (35)

1. Jordan VC: Tamoxifen: A most unlikely pioneering medicine. Nat Rev Drug Discov 2:205-213, 2003
2. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618, 1998
3. Klijn JG, Berns EM, Foekens JA: Other endocrine and biological agents in the treatment of advanced breast cancer, in Miller WR, Ingle JN (ed): Endocrine Therapy in Breast Cancer. New York, NY, Marcel Dekker, 2002
4. Brown PO, Botstein D: Exploring the new world of the genome with DNA microarrays. Nat Genet 21:33-37, 1999
5. Holloway RW, Mehta RS, Finkler NJ, et al: Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 87:8-16, 2002
6. Hedenfalk I, Duggan D, Chen Y, et al: Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539-548, 2001
7. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
8. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
9. van de Vijver MJ, He YD, van't Veer U, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002
10. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
11. Chang JC, Wooten EC, Tsimelzon A, et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369, 2003
12. Hayward JL, Carbone PP, Heuson JC, et al: Assessment of response to therapy in advanced breast cancer: A project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 39:1289-1294, 1977
13. Foekens JA, Peters HA, Grebenchtchikov N, et al: High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61:5407-5414, 2001
14. Martens JW, Sieuwerts AM, Bolt-deVries J, et al: Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. Thromb Haemost 89:393-404, 2003
15. Weigelt B, Glas AM, Wessels LF, et al: Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 100:15901-15905, 2003
16. Yang YH, Dudoit S, Luu P, et al: Normalization for cDNA microarray data: A robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30:e15, 2002
17. Tang S, Han H, Bajic VB: ERGDB: Estrogen Responsive Genes Database. Nucleic Acids Res 32:D533-D536, 2004
18. Pusztai L, Ayers M, Stec J, et al: Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 9:2406-2415, 2003
19. Gruvberger S, Ringner M, Chen Y, et al: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61:5979-5984, 2001
20. Charpentier AH, Bednarek AK, Daniel RL, et al: Effects of estrogen on global gene expression: Identification of novel targets of estrogen action. Cancer Res 60:5977-5983, 2000
21. Frasor J, Danes JM, Komm B, et al: Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562-4574, 2003
22. Mandlekar S, Kong AN: Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6:469-477, 2001
23. Iacobuzio-Donahue CA, Argani P, Hempen PM, et al: The desmoplastic response to infiltrating breast carcinoma: Gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res 62:5351-5357, 2002
24. Mackay A, Jones C, Dexter T, et al: cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22: 2680-2688, 2003
25. Jones C, Mackay A, Grigoriadis A, et al: Expression profiling of purified normal human luminal and myoepithelial breast cells: Identification of novel prognostic markers for breast cancer. Cancer Res 64:3037-3045, 2004
26. Paik S, Shak S, Tang G, et al: Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients-NSABP studies B-20 and B-14. Breast Cancer Res Treat 82:510-S16, 2003
27. Ma XJ, Wang Z, Ryan PD, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5:607-616, 2004
28. Hyman E, Kauraniemi P, Hautaniemi S, et al: Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 62: 6240-6245, 2002
29. Osborne RJ, Hamshere MG: A genomewide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. Cancer Res 60:3706-37012, 2000
30. DeMarchis L, Cropp C, Sheng ZM, et al: Candidate target genes for loss of heterozygosity on human chromosome 17q21. Br J Cancer 90:2384-2389, 2004
31. Ding SL, Sheu LF, Yu JC, et al: Abnormality of the DNA double-strand-break checkpoint/ repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade. Br J Cancer 90:1995-2001, 2004
32. Lipton A, Ali SM, Leitzel K, et al: Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 21:1967-1972, 2003
33. Ferrero-Pous M, Hacene K, Bouchet C, et al: Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 6:4745-4754, 2000
34. Wright C, Angus B, Nicholson S, et al: Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49:2087-2090, 1989
35. Hayes DF: Tamoxifen: Dr. Jekyll and Mr. Hyde? J Natl Cancer Inst 96:895-897, 2004